Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurology›Condition·Updated Jun 27, 2026·v1

Restless Legs Syndrome

Restless Legs Syndrome is a prevalent, treatable disorder driven by central iron deficiency and dopaminergic dysregulation. Diagnosis rests on the four IRLSSG criteria plus exclusion of secondary causes, with ferritin measurement guiding iron therapy. First‑line management uses pregabalin (or gabapentin) and iron repletion; dopamine agonists are added cautiously, monitoring for augmentation. Severe or refractory disease may require rotigotine, opioid‑naloxone, or referral for neuromodulation. Early, guideline‑aligned treatment improves sleep, reduces cardiovascular risk, and prevents chronic disability.

High Evidence141 references·1,659 words·7 min read·v1
neurologysleep-medicinemovement-disorderrestless-legs-syndrome

Quick Reference

RxDrug of choicePregabalin (150 mg PO BID, titrate to 300 mg BID)
AltAlternativesGabapentin, Pramipexole, Rotigotine patch, Oxycodone‑naloxone PR
⊘AvoidHigh‑dose oral dopamine agonists (>0.5 mg pramipexole) as first‑line; dopamine agonists in pregnancy (Category C)
DxTest of choiceSerum ferritin & TSAT; IRLS questionnaire for severity
ScKey scoreIRLS ≥15 → pharmacologic escalation; IRLS ≥30 → high risk of augmentation
→When to referIRLS ≥20 despite optimal therapy, evidence of augmentation, or coexistent sleep‑disordered breathing
Correct iron deficiency first, start pregabalin for most patients, add dopamine agonists only if needed, and vigilantly monitor for augmentation.
Restless Legs Syndrome (RLS) is a common sensorimotor disorder marked by an irresistible urge to move the legs, worsening at rest and in the evening, and relieved by activity. Diagnosis relies on the IRLSSG criteria, severity is graded by the IRLS score, and treatment follows a stepwise algorithm emphasizing iron repletion, gabapentinoids, dopaminergic agents, and opioids while avoiding augmentation.

Overview and Recommendations

Background

  • •RLS - a sensorimotor disorder defined by four IRLSSG criteria (urge to move, worsening at rest, relief with movement, evening predominance) - affects 3‑10 % of adults and up to 15 % of those >70 y, with a female‑to‑male ratio of ~1.5:1.
  • •Pathophysiology centers on brain iron deficiency and dopaminergic hypo‑activity; low ferritin correlates with reduced striatal dopamine synthesis, while up‑regulated D2 receptors reflect compensatory signaling.
  • •Genetic susceptibility (MEIS1, BTBD9, LMX1B) accounts for ~50 % of variance and converges on iron handling and dopamine neuron development.
  • •Secondary causes - iron deficiency, chronic kidney disease, pregnancy, and neurologic disorders (Parkinson disease, multiple sclerosis) - often resolve when the underlying condition is treated.
  • •Severity is quantified by the International RLS Study Group Rating Scale (IRLS 0‑40); scores ≥15 trigger pharmacologic escalation, and ≥30 predict augmentation risk.

Evaluation

  • •Suspect RLS in any patient with nocturnal leg discomfort that improves with walking, especially if symptoms occur ≥3 days/week and last >5 minutes per episode.
  • •Ask about circadian pattern, relief with movement, and impact on sleep; screen for red‑flags such as sudden severe leg pain, focal neurologic deficits, or respiratory compromise (FVC <15 mL/kg).
  • •Examine for involuntary leg movements during a 5‑minute seated rest; observe for periodic limb movements (PLMS) on bedside EMG if available.
  • •Order serum ferritin and transferrin saturation (TSAT) on the initial visit; ferritin <75 µg/L or TSAT <20 % signals brain iron deficiency and prompts iron therapy.
  • •Check renal function (eGFR), thyroid panel, and complete blood count to rule out secondary contributors (CKD, hypothyroidism, anemia).
  • •If pregnancy is possible, obtain a urine β‑hCG; treat iron deficiency promptly because ferritin <30 µg/L predicts severe gestational RLS.
  • •Consider quantitative sensory testing or nerve‑conduction studies only when peripheral neuropathy is suspected (e.g., abnormal sensory exam).
  • •Apply the IRLSSG 4‑item screen; a positive result plus ferritin ≥75 µg/L allows a provisional diagnosis, but specialist confirmation is recommended for moderate‑severe disease.
  • •For refractory or atypical cases (restless abdomen, early‑onset <40 y), obtain polysomnography with leg EMG to quantify PLMS index (>15 events/h supports severe phenotype).
  • •Document baseline IRLS score; repeat every 4 weeks to gauge treatment response and to identify early augmentation (increase ≥10 points after ≥3 months of dopaminergic therapy).

Management

  • •Initiate iron repletion when ferritin <75 µg/L or TSAT <20 %: IV ferric carboxymaltose 750 mg on day 0 and day 5 (repeat q12 weeks if needed).
  • •For dopamine‑naïve patients with IRLS 11‑20, start 150 mg PO BID; titrate to 300 mg BID (max 600 mg) over 2 weeks - reduces IRLS by ~12 points and avoids augmentation.
  • •If pregabalin is contraindicated (eGFR <30 mL/min), use 300 mg PO TID, titrating to 900 mg/day as tolerated.
  • •When non‑dopaminergic agents fail or IRLS ≥21, add a dopamine agonist: 0.125 mg PO at bedtime, increase by 0.125 mg weekly to max 0.75 mg; monitor for impulse‑control disorders and augmentation.
  • •Alternatively, apply a transdermal patch 2 mg/24 h; increase to 4 mg/24 h after 12 h if symptoms persist - provides steady dopaminergic stimulation with lower augmentation risk.
  • •Reserve ‑naloxone PR 10 mg/5 mg PO BID (titrate to 20 mg/10 mg BID) for severe, refractory RLS (IRLS ≥30) after dopaminergic failure; contraindicated in severe COPD or untreated sleep‑apnoea.
  • •Avoid high‑dose oral dopamine agonists (>0.5 mg pramipexole) as first‑line rescue; they are linked to life‑threatening impulse‑control and augmentation events.
  • •Monitor serum ferritin every 3 months while on dopaminergic therapy; re‑infuse iron if ferritin falls below 75 µg/L to mitigate augmentation.
  • •Screen for augmentation at each visit: a rise in IRLS ≥10 points after ≥3 months of stable dopaminergic dose signals need to switch to a non‑dopaminergic agent.
  • •Educate patients on sleep hygiene (regular bedtime, cool room, caffeine avoidance) and leg‑stretching exercises before sleep - these non‑pharmacologic measures can lower IRLS by 4‑5 points.
  • •Refer to a sleep‑movement specialist if IRLS remains ≥20 despite optimal pharmacotherapy, if augmentation persists, or if comorbid obstructive sleep apnoea is suspected.
  • •Discharge criteria: IRLS ≤10, ferritin ≥75 µg/L, stable medication regimen for ≥2 weeks, and patient able to adhere to sleep‑hygiene plan.

Board Review — High Yield

  • •Four IRLSSG criteria, urge, rest‑worsening, movement relief, evening predominance.
  • •Brain iron deficiency, core driver; ferritin <75 µg/L predicts response to IV iron.
  • •Augmentation, paradoxical worsening after ≥3 months of dopaminergic therapy; risk ↑ with baseline IRLS ≥30.
  • •Pregabalin, first‑line non‑dopaminergic agent; 150‑300 mg BID, NNT = 5 for ≥50 % IRLS improvement.
  • •Rotigotine patch, steady dopaminergic delivery; 2‑4 mg/24 h useful in augmentation‑prone patients.
  • •Ferric carboxymaltose, IV iron regimen (750 mg × 2) reduces IRLS by ~8 points; use when ferritin <75 µg/L.
  • •Pregnancy RLS, avoid dopamine agonists; treat with oral/IV iron and gabapentin if needed after first trimester.
  • •IRLS severity thresholds, 0‑10 mild, 11‑20 moderate, 21‑30 severe, 31‑40 very severe.

Deep Dive — Evidence Details

References

  1. [1]

    Oertel W, Trenkwalder C, Beneš H et al.. “Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.” The Lancet. Neurology (2011). PMID: 21705273 ↗

    L4RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  2. [2]

    Garcia-Borreguero D, Larrosa O, Williams AM et al.. “Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study.” Neurology (2010). PMID: 20427750 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Prognosis & Natural History
  3. [3]

    Bauer A, Cassel W, Benes H et al.. “Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.” Neurology (2016). PMID: 27164714 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  4. [4]

    Manconi M, Ferri R, Zucconi M et al.. “Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.” Neurology (2011). PMID: 21715702 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation
  5. [5]

    Klepitskaya O, Liu Y, Sharma S et al.. “Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease.” Neurology (2018). PMID: 30111549 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  6. [6]

    Pérez-Díaz H, Iranzo A, Rye DB et al.. “Restless abdomen: a phenotypic variant of restless legs syndrome.” Neurology (2011). PMID: 21917771 ↗

    L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  7. [7]

    Li Y, Munger KL, Batool-Anwar S et al.. “Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women.” Neurology (2012). PMID: 22539566 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations & Prevention
  8. [8]

    Schrag A, Bohlken J, Dammertz L et al.. “Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease.” JAMA neurology (2023). PMID: 36342675 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  9. [9]

    Garcia-Borreguero D, Anguizola D, Carvallo C et al.. “Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials.” CNS drugs (2025). PMID: 40467956 ↗

    L2RCTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  10. [10]

    Garcia-Borreguero D, Aragón AG, Moncada B et al.. “Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study.” CNS drugs (2024). PMID: 38246901 ↗

    L1RCTCited in: Definition, Classification & Nomenclature
  11. [11]

    Garcia-Borreguero D, Black J, Earley CJ et al.. “Rethinking clinical trials in restless legs syndrome: A roadmap.” Sleep medicine reviews (2024). PMID: 39102777 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Complications
  12. [12]

    Du D, Qin J, Tang X et al.. “Smoking and risk of restless leg syndrome: a systematic review, meta-analysis, and Mendelian randomisation.” Journal of global health (2026). PMID: 41855429 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  13. [13]

    Gupta A, Chhabra V, Shinkre R et al.. “Worldwide pooled prevalence of restless legs syndrome in patients with coronary artery disease: A systematic review and meta-analysis.” Sleep medicine (2025). PMID: 41172563 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  14. [14]

    Dumont S, Bloch V, Lillo-Lelouet A et al.. “Parasomnias and sleep-related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects.” Journal of sleep research (2024). PMID: 39243188 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization)
  15. [15]

    Schormair B, Zhao C, Bell S et al.. “Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.” The Lancet. Neurology (2017). PMID: 29029846 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  16. [16]

    Hübner A, Krafft A, Gadient S et al.. “Characteristics and determinants of restless legs syndrome in pregnancy: a prospective study.” Neurology (2013). PMID: 23390174 ↗

    L2COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations & Prevention
  17. [17]

    Akçimen F, Chia R, Saez-Atienzar S et al.. “Genomic Analysis Identifies Risk Factors in Restless Legs Syndrome.” Annals of neurology (2024). PMID: 39078117 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  18. [18]

    Trenkwalder C, Allen R, Högl B et al.. “Comorbidities, treatment, and pathophysiology in restless legs syndrome.” The Lancet. Neurology (2018). PMID: 30244828 ↗

    L5CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  19. [19]

    Stefansson H, Rye DB, Hicks A et al.. “A genetic risk factor for periodic limb movements in sleep.” The New England journal of medicine (2007). PMID: 17634447 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  20. [20]

    Paulus W, Trenkwalder C. “Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome.” The Lancet. Neurology (2006). PMID: 16987735 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  21. [21]

    Jankovic J. “Treatment of hyperkinetic movement disorders.” The Lancet. Neurology (2009). PMID: 19679276 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  22. [22]

    Heim B, Djamshidian A, Heidbreder A et al.. “Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?” Neurology (2016). PMID: 27261093 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Complications
  23. [23]

    Szentkirályi A, Völzke H, Hoffmann W et al.. “Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies.” Neurology (2014). PMID: 24808014 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  24. [24]

    Salminen AV, Rimpilä V, Polo O. “Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease).” Neurology (2014). PMID: 24789861 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  25. [25]

    Hattan E, Chalk C, Postuma RB. “Is there a higher risk of restless legs syndrome in peripheral neuropathy?” Neurology (2008). PMID: 19038854 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  26. [26]

    Lee BY, Kim J, Connor JR et al.. “Involvement of the central somatosensory system in restless legs syndrome: A neuroimaging study.” Neurology (2018). PMID: 29695597 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  27. [27]

    Bialer M. “How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)?” Epilepsia (2012). PMID: 23205958 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Neurorehabilitation, Symptomatic & Supportive Care
  28. [28]

    Wang L, Hao W, Wang D et al.. “Modulation of spinal and cortical neuronal excitability by transcutaneous spinal direct current stimulation in restless legs syndrome.” Sleep medicine (2026). PMID: 41616577 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  29. [29]

    Rizzo G, Tonon C, Testa C et al.. “Abnormal medial thalamic metabolism in patients with idiopathic restless legs syndrome.” Brain : a journal of neurology (2012). PMID: 23183234 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  30. [30]

    Connor JR, Ponnuru P, Wang XS et al.. “Profile of altered brain iron acquisition in restless legs syndrome.” Brain : a journal of neurology (2011). PMID: 21398376 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  31. [31]

    Cervenka S, Pålhagen SE, Comley RA et al.. “Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.” Brain : a journal of neurology (2006). PMID: 16816393 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  32. [32]

    Yepes G, Guitart X, Rea W et al.. “Targeting hypersensitive corticostriatal terminals in restless legs syndrome.” Annals of neurology (2017). PMID: 29171915 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  33. [33]

    Karroum EG, Bachmann CG, Bronstone A et al.. “Efficacy and safety of tonic motor activation (TOMAC) for restless legs syndrome as adjunctive and monotherapy: An individual participant data systematic review and meta-analysis.” Sleep medicine (2026). PMID: 41581285 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  34. [34]

    Lanza G, Mogavero MP, Ferri R et al.. “Motor cortex excitability in restless legs syndrome: A systematic review and insights into pathophysiology via transcranial magnetic stimulation.” Sleep medicine reviews (2024). PMID: 39626363 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  35. [35]

    Pani T, Mogavero MP, Ferri R et al.. “Unraveling the pathophysiology of restless legs syndrome from multimodal MRI techniques: A systematic review.” Sleep medicine (2024). PMID: 39561671 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation
  36. [36]

    Khan A, Kumar H, Rai KD et al.. “Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis.” Frontiers in neurology (2025). PMID: 39839869 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Special Populations & Prevention
  37. [37]

    Nepožitek J, Dostálová S, Jirásek M et al.. “Sleep in Functional Motor Disorders: A Case-Control Polysomnographic Study.” Journal of sleep research (2025). PMID: 40741637 ↗

    L4CASE_CONTROLCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  38. [38]

    Alonso-Navarro H, García-Martín E, Agúndez JAG et al.. “Association between restless legs syndrome and other movement disorders.” Neurology (2019). PMID: 31004074 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  39. [39]

    Trenkwalder C, Allen R, Högl B et al.. “Restless legs syndrome associated with major diseases: A systematic review and new concept.” Neurology (2016). PMID: 26944272 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  40. [40]

    Li Y, Wang W, Winkelman JW et al.. “Prospective study of restless legs syndrome and mortality among men.” Neurology (2013). PMID: 23761622 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications
  41. [41]

    Postuma RB, Iranzo A, Hu M et al.. “Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.” Brain : a journal of neurology (2019). PMID: 30789229 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  42. [42]

    Fulda S, Wetter TC. “Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.” Brain : a journal of neurology (2007). PMID: 17932100 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  43. [43]

    Marrie RA, Reider N, Cohen J et al.. “A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 25533301 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  44. [44]

    Chen H, Cortese M, Flores-Torres MH et al.. “Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42267700 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  45. [45]

    Schade R, Andersohn F, Suissa S et al.. “Dopamine agonists and the risk of cardiac-valve regurgitation.” The New England journal of medicine (2007). PMID: 17202453 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  46. [46]

    Clemens S, Rye D, Hochman S. “Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective.” Neurology (2006). PMID: 16832090 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  47. [47]

    Auerbach S, Walters AS. “Restless legs syndrome: a predictor of lower physical function.” Neurology (2014). PMID: 24598710 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  48. [48]

    Zhang C, Li Y, Malhotra A et al.. “Restless legs syndrome status as a predictor for lower physical function.” Neurology (2014). PMID: 24598708 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  49. [49]

    Gao X, Schwarzschild MA, Wang H et al.. “Obesity and restless legs syndrome in men and women.” Neurology (2009). PMID: 19349606 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
  50. [50]

    Martikainen MH, Ng YS, Gorman GS et al.. “Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease.” JAMA neurology (2016). PMID: 27111573 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Prevention
  51. [51]

    Catoire H, Dion PA, Xiong L et al.. “Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis.” Annals of neurology (2011). PMID: 21710629 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  52. [52]

    Haba-Rubio J, Marti-Soler H, Marques-Vidal P et al.. “Prevalence and determinants of periodic limb movements in the general population.” Annals of neurology (2016). PMID: 26703954 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  53. [53]

    Gómez-Choco MJ, Iranzo A, Blanco Y et al.. “Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2007). PMID: 17613610 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  54. [54]

    Manconi M, Rocca MA, Ferini-Strambi L et al.. “Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage.” Multiple sclerosis (Houndmills, Basingstoke, England) (2007). PMID: 17942519 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  55. [55]

    Kaminska M, Kimoff RJ, Benedetti A et al.. “Obstructive sleep apnea is associated with fatigue in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 22183937 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  56. [56]

    Altalbawy FMA, Kareem M, Sanghvi G et al.. “Prevalence of restless legs syndrome during pregnancy: a systematic review and meta-analysis.” Sleep medicine (2026). PMID: 41980535 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
  57. [57]

    Thrash GW, Wang E, Brockington D et al.. “Neuromodulation for Restless Legs Syndrome: A Systematic Review and Mechanistic Considerations for Spinal Cord Stimulation.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 41806217 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
  58. [58]

    Iftikhar IH, Rao ST, Albisher E et al.. “Benefit-risk comparison of gabapentin enacarbil versus pregabalin for restless legs syndrome: A dose-response model-based network meta-analysis.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 41731161 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
  59. [59]

    Bassetti CLA, Welter LS, Montes-Martinez M et al.. “Epidemiology and Economic Burden of Sleep Disorders in Europe.” European journal of neurology (2026). PMID: 41689412 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  60. [60]

    Mathieu S, Rat AC, Sellam J. “Prevalence and impact of sleep disorders in osteoarthritis: A systematic review and meta-analysis.” Osteoarthritis and cartilage open (2025). PMID: 41550413 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  61. [61]

    Hornyak M, Rupp A, Riemann D et al.. “Low-dose hydrocortisone in the evening modulates symptom severity in restless legs syndrome.” Neurology (2008). PMID: 18443313 ↗

    L4RCTCited in: Clinical Presentation
  62. [62]

    Manconi M, Ferri R, Zucconi M et al.. “Dissociation of periodic leg movements from arousals in restless legs syndrome.” Annals of neurology (2012). PMID: 22718547 ↗

    L1RCTCited in: Clinical Presentation
  63. [63]

    Hermann DM, Bassetti CL. “Sleep-related breathing and sleep-wake disturbances in ischemic stroke.” Neurology (2009). PMID: 19841384 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Special Populations & Prevention
  64. [64]

    Bachmann CG, Rolke R, Scheidt U et al.. “Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome.” Brain : a journal of neurology (2010). PMID: 20194142 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
  65. [65]

    Tam J, Garcia Borreguero D, DelRosso LM. “Exploring the obstructive sleep apnea and restless legs syndrome comorbidity (Co-ROSA): A systematic review.” Sleep medicine reviews (2025). PMID: 41061431 ↗

    L5SR_OBSCited in: Clinical Presentation
  66. [66]

    Maggi G, Barone A, Mastromarino C et al.. “Prevalence and clinical profile of patients with restless legs syndrome in Parkinson's disease: A meta-analysis.” Sleep medicine (2024). PMID: 39033665 ↗

    L5SR_OBSCited in: Clinical Presentation
  67. [67]

    Wang SH, Chen XY, Wang XP. “Jidong Restless Legs Syndrome Cohort Study: Objectives, Design, and Baseline Screening.” Frontiers in neurology (2021). PMID: 34721252 ↗

    L2COHORTCited in: Clinical Presentation
  68. [68]

    Balian EA, Nadryan NM, Atabekyan LG et al.. “Antidepressant withdrawal-induced de novo restless legs syndrome: a case report.” Sleep medicine (2026). PMID: 41785584 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  69. [69]

    Joyce JB, Patarroyo Rodriquez L, Sola CL. “Case Report: Near-fatal adverse effects of dopamine agonist for the treatment of restless legs syndrome.” Frontiers in pharmacology (2025). PMID: 41244828 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Acute Management & Time-Critical Pathway
  70. [70]

    Li Y, Li Y, Winkelman JW et al.. “Prospective study of restless legs syndrome and total and cardiovascular mortality among women.” Neurology (2017). PMID: 29247069 ↗

    L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
  71. [71]

    Hermann DM, Bassetti CL. “Role of sleep-disordered breathing and sleep-wake disturbances for stroke and stroke recovery.” Neurology (2016). PMID: 27488603 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
  72. [72]

    Ohayon MM, Bagai K, Roberts LW et al.. “Refining duration and frequency thresholds of restless legs syndrome diagnosis criteria.” Neurology (2016). PMID: 27770066 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  73. [73]

    Scher AI, Ross GW, Sigurdsson S et al.. “Midlife migraine and late-life parkinsonism: AGES-Reykjavik study.” Neurology (2014). PMID: 25230997 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  74. [74]

    Lam EM, Shepard PW, St Louis EK et al.. “Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2.” Neurology (2013). PMID: 23749798 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  75. [75]

    Abler B, Hahlbrock R, Unrath A et al.. “At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists.” Brain : a journal of neurology (2009). PMID: 19567700 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  76. [76]

    Koo BB, Abdelfattah A, Eysa A et al.. “The Melanocortin and Endorphin Neuropeptides in Patients with Restless Legs Syndrome.” Annals of neurology (2024). PMID: 38308537 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  77. [77]

    Palsa K, Sahu AP, Rye DB et al.. “Cerebrospinal Fluid from Restless Legs Syndrome Patients Reduces Iron Uptake in Blood-Brain Barrier Endothelial Cells by Disrupting the Regulation of Transferrin Receptors.” Annals of neurology (2026). PMID: 41947413 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  78. [78]

    Ke L, Chen Z, Fan F et al.. “Association of Statin use with Parkinson's Disease Progression in a Prospective Cohort Study and Multi-omics Analyses.” Journal of molecular neuroscience : MN (2026). PMID: 41721963 ↗

    L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  79. [79]

    Makwana A, Sablok R, Adler P et al.. “Phenotypes and course of restless legs syndrome in acute stroke survivors - a prospective observational cohort study.” Sleep medicine (2025). PMID: 41389618 ↗

    L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  80. [80]

    Zhang J, Huang Y, Liang J et al.. “Efficacy and safety of pharmacological treatments for restless legs syndrome in hemodialysis patients: a systematic review and meta-analysis.” Frontiers in neurology (2026). PMID: 42246040 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  81. [81]

    Stryjewska ES, Jurga S, Pietraszkiewicz F et al.. “Sleep disorders in patients with spinal cord injury: A comprehensive review of assessment strategies and available treatment.” Neurologia i neurochirurgia polska (2025). PMID: 41182065 ↗

    L5SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  82. [82]

    Yan F, Cheng Y, Feng S. “Association between serum GFAP, BDNF and NfL levels and clinical symptoms in restless legs syndrome: a case-control study.” Sleep medicine (2025). PMID: 40706400 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  83. [83]

    Mizoguchi T, Okazaki Y, Ichiba T. “Sudden-onset restless legs syndrome due to acute cerebral hemorrhage.” The American journal of emergency medicine (2026). PMID: 41930800 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  84. [84]

    Wang P, Yu L, Zhang L et al.. “Variant restless legs syndrome masquerading as refractory shoulder pain: a case report and literature review.” Frontiers in medicine (2026). PMID: 41567687 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  85. [85]

    Tiralongo G, De Stefano D, Volponi C et al.. “Sleep-related painful erection: the first case in a child.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2025). PMID: 40160009 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  86. [86]

    Cui Y, Huang Q, Du Y et al.. “Secondary overactive bladder syndrome with restless legs syndrome following cerebral infarction: report of 2 cases.” BMC geriatrics (2025). PMID: 40133822 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  87. [87]

    Allen RP, Chen C, Garcia-Borreguero D et al.. “Comparison of pregabalin with pramipexole for restless legs syndrome.” The New England journal of medicine (2014). PMID: 24521108 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder)
  88. [88]

    Trenkwalder C, Beneš H, Grote L et al.. “Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.” The Lancet. Neurology (2013). PMID: 24140442 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  89. [89]

    Trenkwalder C, Benes H, Poewe W et al.. “Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.” The Lancet. Neurology (2008). PMID: 18515185 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  90. [90]

    Winkelman JW, Sethi KD, Kushida CA et al.. “Efficacy and safety of pramipexole in restless legs syndrome.” Neurology (2006). PMID: 16931507 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  91. [91]

    Oertel WH, Benes H, Bodenschatz R et al.. “Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).” Neurology (2006). PMID: 16931508 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
  92. [92]

    Silva MA, Duarte GS, Camara R et al.. “Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.” Neurology (2017). PMID: 28490647 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification
  93. [93]

    Veatch OJ, Keenan BT, Gehrman PR et al.. “Pleiotropic genetic effects influencing sleep and neurological disorders.” The Lancet. Neurology (2017). PMID: 28102151 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  94. [94]

    Chenini S, Barateau L, Guiraud L et al.. “Association of Sleep Disruption With Daytime Sleepiness in Patients With Restless Legs Syndrome.” Neurology (2025). PMID: 40112236 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  95. [95]

    Gorantla S, Gorijala VK, Trotti LM. “Suggested immobilization test in RLS clinical trials: A systematic review and methodological appraisal.” Sleep medicine (2025). PMID: 41038062 ↗

    L1TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification
  96. [96]

    Elfahl AM, Elfeky HM. “Progressive muscle relaxation versus manual lymphatic drainage on restless leg syndrome and sleep quality in hemodialysis patients: Randomized Controlled Trial.” Journal of bodywork and movement therapies (2025). PMID: 40954628 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
  97. [97]

    Bachmann CG, Lanza G, Senel GB et al.. “Neurostimulation for restless legs syndrome: A systematic review and meta-analysis.” Sleep medicine reviews (2026). PMID: 42001819 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification
  98. [98]

    Nguyen HT, Hai Ly NT, Liao WC et al.. “The association of restless leg syndrome with sleep quality, depression symptoms, and quality of life in pregnancy: A systematic review and meta-analysis.” Sleep medicine (2026). PMID: 41932169 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Special Populations & Prevention
  99. [99]

    Iftikhar IH, Lacki OA, Albisher E et al.. “Placebo and nocebo responses in gabapentin enacarbil and pregabalin trials for restless legs syndrome: time-course model-based network meta-analysis and meta-analysis of proportions.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 41882288 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification
  100. [100]

    Harrison EG, Keating JL, Morgan P. “Novel Exercises for Restless Legs Syndrome: A Randomized, Controlled Trial.” Journal of the American Board of Family Medicine : JABFM (2018). PMID: 30201675 ↗

    L1RCTCited in: Acute Management & Time-Critical Pathway
  101. [101]

    Duss SB, Bauer-Gambelli SA, Bernasconi C et al.. “Frequency and evolution of sleep-wake disturbances after ischemic stroke: A 2-year prospective study of 437 patients.” Sleep medicine (2022). PMID: 36446142 ↗

    L3COHORTCited in: Acute Management & Time-Critical Pathway
  102. [102]

    Högl B, Oertel WH, Schollmayer E et al.. “Transdermal rotigotine for the perioperative management of restless legs syndrome.” BMC neurology (2012). PMID: 23009552 ↗

    L2TRIAL_NONRANDOMCited in: Acute Management & Time-Critical Pathway
  103. [103]

    Giannaki CD, Sakkas GK, Hadjigeorgiou GM et al.. “Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome.” ASAIO journal (American Society for Artificial Internal Organs : 1992) (2010). PMID: 21245801 ↗

    L2TRIAL_NONRANDOMCited in: Acute Management & Time-Critical Pathway
  104. [104]

    Chokroverty S. “Long-term management issues in restless legs syndrome.” Movement disorders : official journal of the Movement Disorder Society (2011). PMID: 21538518 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Time-Critical Pathway
  105. [105]

    Brunetti V, Rollo E, Broccolini A et al.. “Sleep and Stroke: Opening Our Eyes to Current Knowledge of a Key Relationship.” Current neurology and neuroscience reports (2022). PMID: 36190654 ↗

    L5REVIEW_NARRATIVECited in: Acute Management & Time-Critical Pathway
  106. [106]

    Shiina T, Suzuki K, Okamura M et al.. “Restless legs syndrome and its variants in acute ischemic stroke.” Acta neurologica Scandinavica (2018). PMID: 30449044 ↗

    L5OTHERCited in: Acute Management & Time-Critical Pathway
  107. [107]

    Allavena C, Bastides F, Moroy A et al.. “The screening and management of sleep disturbances in people living with HIV: Delphi consensus.” Journal of sleep research (2023). PMID: 37941027 ↗

    L5OTHERCited in: Acute Management & Time-Critical Pathway
  108. [108]

    Trenkwalder C, Canelo M, Lang M et al.. “Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.” Sleep medicine (2015). PMID: 26896370 ↗

    L5OTHERCited in: Acute Management & Time-Critical Pathway
  109. [109]

    Mohamed RG, Sarhan K, Hegazi A et al.. “Efficacy and safety of tonic motor activation for the treatment of restless legs syndrome: A meta-analysis of randomized controlled trials.” Sleep medicine (2025). PMID: 40381601 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  110. [110]

    Richards KC, Fry LM, Lozano AJ et al.. “Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial.” Journal of the American Medical Directors Association (2025). PMID: 39909068 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  111. [111]

    Earley CJ, García-Borreguero D, Falone M et al.. “Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial.” Sleep (2024). PMID: 38625730 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  112. [112]

    Xu J, Qi Y, Tang Y et al.. “Improvement of restless leg syndrome in maintenance hemodialysis patients with limb ischemic preconditioning: a single-center randomized controlled clinical trial.” Renal failure (2023). PMID: 38047534 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  113. [113]

    Roy A, Ojile J, Kram J et al.. “Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.” Sleep (2023). PMID: 37439365 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  114. [114]

    Ozdogar AT, Ertekin O, Kahraman T et al.. “Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial.” Multiple sclerosis and related disorders (2022). PMID: 36603295 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  115. [115]

    Jadidi A, Rezaei Ashtiani A, Khanmohamadi Hezaveh A et al.. “Therapeutic effects of magnesium and vitamin B6 in alleviating the symptoms of restless legs syndrome: a randomized controlled clinical trial.” BMC complementary medicine and therapies (2022). PMID: 36587225 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  116. [116]

    Bae H, Cho YW, Kim KT et al.. “Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.” Sleep medicine (2021). PMID: 34157632 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  117. [117]

    Chenini S, Rassu AL, Barateau L et al.. “Increased Blood Pressure Dipping in Restless Legs Syndrome With Rotigotine: A Randomized Trial.” Movement disorders : official journal of the Movement Disorder Society (2020). PMID: 32875658 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  118. [118]

    Song ML, Park KM, Motamedi GK et al.. “Cognitive behavioral therapy for insomnia in restless legs syndrome patients.” Sleep medicine (2020). PMID: 32861015 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  119. [119]

    Jafarimanesh H, Vakilian K, Mobasseri S. “Thermo-therapy and cryotherapy to decrease the symptoms of restless leg syndrome during the pregnancy: A randomized clinical trial.” Complementary therapies in medicine (2020). PMID: 32444058 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  120. [120]

    Iranzo A, Cochen De Cock V, Fantini ML et al.. “Sleep and sleep disorders in people with Parkinson's disease.” The Lancet. Neurology (2024). PMID: 38942041 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  121. [121]

    Barateau L, Chenini S, Rassu AL et al.. “Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome.” Neurology (2022). PMID: 35918167 ↗

    L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  122. [122]

    Andrade C. “Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes.” The Journal of clinical psychiatry (2026). PMID: 41499180 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Special Populations & Prevention
  123. [123]

    d'Onofrio F, Cropano M, Panzino G et al.. “Migraine and Restless Legs Syndrome: A Meta-Analysis.” Journal of sleep research (2025). PMID: 40968706 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  124. [124]

    Mogavero MP, Karroum EG, Lanza G et al.. “Pharmacological impact on sleep architecture and polysomnographic measures in Restless Legs Syndrome: A systematic review.” Sleep medicine reviews (2025). PMID: 40779961 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  125. [125]

    Huang L, Li S, Zeng J. “Analysis of trends and hotspots in the research on sleep disorders of maintenance hemodialysis patients based on bibliometrics.” Frontiers in psychiatry (2025). PMID: 40661883 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
  126. [126]

    Ebrahimi H, Ranjbar MS, Ebrahimi N et al.. “Prevalence of restless legs syndrome in Pakistan: a systematic review and meta-analysis across diverse study populations.” BMC neurology (2026). PMID: 42298475 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  127. [127]

    Winkelman JW, Berkowski JA, DelRosso LM et al.. “Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2025). PMID: 39324694 ↗

    L1GUIDELINECited in: Complications, Prognosis & Natural History, Special Populations & Prevention
  128. [128]

    Chen JM, Chang CC, Li YL et al.. “Efficacy and Safety of Acupuncture for Restless Legs Syndrome in Patients with End-Stage Renal Disease: A Randomized-Controlled Trial at Hospital-Based Hemodialysis Center.” Journal of integrative and complementary medicine (2024). PMID: 38770610 ↗

    L1RCTCited in: Complications, Prognosis & Natural History
  129. [129]

    Ozdogar AT, Kalron A. “The Efficacy of Non-Pharmacological Interventions for Sleep Disorders in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis.” Journal of sleep research (2025). PMID: 40325863 ↗

    L2SR_OBSCited in: Complications
  130. [130]

    Saeki Y, Sumi Y, Ozaki Y et al.. “Proposal for Managing Cancer-Related Insomnia: A Systematic Literature Review of Associated Factors and a Narrative Review of Treatment.” Cancer medicine (2024). PMID: 39584650 ↗

    L5SR_OBSCited in: Complications, Special Populations & Prevention
  131. [131]

    Kushida CA, Becker PM, Ellenbogen AL et al.. “Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.” Neurology (2009). PMID: 19188575 ↗

    L1RCTCited in: Prognosis & Natural History
  132. [132]

    Hornyak M, Kaube H. “Long-Term treatment of a patient with severe restless legs syndrome using intrathecal morphine.” Neurology (2012). PMID: 23197746 ↗

    L4CASE_REPORTCited in: Prognosis & Natural History
  133. [133]

    Singh H, Baker FC, Ojile J et al.. “Efficacy and safety of TOMAC for treatment of medication-naïve and medication-refractory restless legs syndrome: A randomized clinical trial and meta-analysis.” Sleep medicine (2024). PMID: 39173210 ↗

    L1SR_MA_RCTCited in: Prognosis & Natural History
  134. [134]

    Winkelman JW, Zackon J, Kilty A. “Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia.” Sleep medicine (2024). PMID: 39260076 ↗

    L1RCTCited in: Prognosis & Natural History
  135. [135]

    Silber MH, Berkowski JA, Buchfuhrer MJ et al.. “An Updated Algorithm for the Management of Restless Legs Syndrome.” Mayo Clinic proceedings (2026). PMID: 42203073 ↗

    L1GUIDELINECited in: Special Populations & Prevention
  136. [136]

    Winkelman JW, Shahar E, Sharief I et al.. “Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study.” Neurology (2008). PMID: 18166705 ↗

    L2OTHERCited in: Special Populations & Prevention
  137. [137]

    Na M, Wu J, Li M et al.. “New onset of restless legs syndrome in pregnancy in a prospective multiracial cohort: Incidence and risk factors.” Neurology (2020). PMID: 33177224 ↗

    L2OTHERCited in: Special Populations & Prevention
  138. [138]

    Pennestri MH, Montplaisir J, Colombo R et al.. “Nocturnal blood pressure changes in patients with restless legs syndrome.” Neurology (2007). PMID: 17420405 ↗

    L4OTHERCited in: Special Populations & Prevention
  139. [139]

    Cesnik E, Casetta I, Turri M et al.. “Transient RLS during pregnancy is a risk factor for the chronic idiopathic form.” Neurology (2010). PMID: 21135386 ↗

    L2OTHERCited in: Special Populations & Prevention
  140. [140]

    Tezuka K, Ito Y, Nishi D. “Restless legs syndrome without insomnia and antenatal depressive symptoms.” BMC pregnancy and childbirth (2025). PMID: 39844093 ↗

    L2RCTCited in: Special Populations & Prevention
  141. [141]

    Abbasi M, Rasoal D, Kharaghani R et al.. “Association between sleep disorders and preeclampsia: a systematic review and meta-analysis.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2024). PMID: 39443163 ↗

    L2SR_OBSCited in: Special Populations & Prevention

Revision History

All updates applied to this page

Loading revisions…